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Objectives:  
To develop a system model of Type 1 diabetes for the purpose of in silico simulation 
for the prediction of long-term glycaemic control outcomes. 
 
Methods:  
The system model is created and identified on a physiological cohort of virtual Type 1 
diabetes patients (n=40).  Integral based identification is used to develop (n=40) 
insulin sensitivity profiles. 
 
Results: 
The n=40 insulin sensitivity profiles provide a driving input for virtual patient trials 
using this model.  The identified models have a total median (90% range) absolute 
percentage error of 1.33% (0.08-7.20%).  The total median (90% range) absolute error 
is 0.12mmol/l (0.01-0.56mmol/l).  The model and integral based identification of SI 
captures all patient dynamics with low error, which leads to more physiological 
behaviour simulation. 
 
Conclusions:  
A simulation tool incorporating n=40 virtual patient data sets to predict long-term 
glycaemic control outcomes from clinical interventions is developed based on a 
physiological Type 1 diabetes metabolic system model.  The overall goal is to utilize 
this model and insulin sensitivity profiles to develop and optimise for self monitoring 
blood glucose and multiple daily injection therapy. 
 
 
 
 
1. INTRODUCTION 
 
Control of Type 1 diabetes is a widely studied and experimented research field.  
Previously published control methods are diverse, using different routes of insulin 
administration and glucose measurement.  Since the 1970s, the closed loop artificial 
endocrine pancreas (AEP) has been heralded as the solution (as reviewed in [1]).  
While no commercial product currently exists, the systems in current clinical use that 
are likely to constitute the components of an extracorporeal artificial pancreas are the 
continuous subcutaneous insulin infusion (CSII) pump and a continuous glucose 
measurement (CGM) device.  Advanced control algorithms and methods to ‘close the 
loop’ have also been widely studied (as reviewed in [2-4]) in spite of early and 
ongoing limitations in sensors and pumps.  Currently, the use of open-loop CGM 
and/or CSII has resulted in at best, a modest clinical advantage over conventional 
methods of insulin administration or multiple daily injection (MDI) (as reviewed in 
[5, 6]).  Additionally, these systems are only used by a small population of Type 1 
diabetics due to high upfront costs, costs of consumables, complexity, and the 
extensive healthcare infrastructure and support required.  Prevalence of CSII use is as 
low as 2% of the Type 1 diabetes population in the UK and up to 15-20% elsewhere 
and the US [7].   
 
Hence, there is a more practical and urgent need to address the large majority of the 
Type 1 diabetes population using conventional glucose measurement i.e. self-
monitoring blood glucose (SMBG) and insulin administration i.e. MDI methods, and 
for whom current conventional or intensive therapies are failing to deliver 
recommended levels of glycaemic control [8].  In the US, over 50% of diagnosed 
diabetics aged 20-64 are deemed ‘out of control’ [9].  The higher accuracy of bedside 
capillary blood glucose meters [10, 11], and the latest insulin analogues for MDI 
therapy [12], coupled with better control methods have the potential to provide better 
care to the majority of outpatient or ambulatory Type 1 diabetics than currently 
observed.  Such techniques must necessarily be simple to implement to ensure broad 
clinical uptake by the diabetes population. 
 
This study reports the development of a system model of the Type 1 insulin-glucose 
regulatory system and its identification on a virtual patient cohort.  The models 
utilised have several novel and unique features. In particular, the insulin model used is 
unique and captures the insulin kinetics of multiple insulin types in a single PK model 
for all shared physiological spaces. The pharmacodynamic model used has not been 
reported previously but bears components of similar nature to other such models used 
in this field due to the need to capture similar physiology.  This study is the basis for a 
novel model-based application to develop a simple and practical adaptive method for 
clinical glycaemic control of Type 1 diabetes using multiple daily injection and self 
monitoring blood glucose measurements.  In addition, the modelling of long term 
clinical outcomes of glycaemic control and their corroboration against clinical 
expectations and studies will be further explored in a subsequent in silico simulation 
on a virtual patient cohort which is also reported in this Journal.  Later, the complex 
interaction of all quantifiable errors in protocol application is investigated in a Monte 
Carlo study to test the robustness of the developed protocol in effectiveness and safety 
[13]. 
 
 
2. MODEL DEVELOPMENT 
 
The system model shown in Equation (1) is an evolution of the model of Chase et al. 
[14] and Wong et al. [15]. 
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where: 
G(t) Plasma glucose concentration [mmol/l] 
CNS Central nervous system glucose uptake [mmol/l.min] 
EGP0-G Endogenous glucose production extrapolated to zero plasma glucose 
concentration [mmol/l.min] 
pG Glucose effectiveness [min-1] 
SI Insulin sensitivity [l/min.mU] 
Q(t) Interstitial (effective) insulin concentration [mU/l] 
RGC(t) Renal glucose clearance [mmol/l.min] 
P(t) Meal plasma glucose rate of appearance [mmol/l.min] 
 
This glucose model differs mathematically from the model developed by Chase et al. 
[14] and Wong et al. [15] in removal of insulin effect saturation and the addition of 
renal glucose clearance rate, RGC(t).  These two studies were on highly dynamic, 
critically-ill patients with high effective insulin resistance and treated with 
intravenous insulin doses.  The removal of the insulin effect saturation was deemed 
suitable for modelling more compliant, insulin sensitive and stable Type 1 diabetes 
patients treated with subcutaneously administered insulin. 
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where: 
RGC(t) Renal glucose clearance [mmol/l.min] 
GFR  Glomerular filtration rate [l/min] 
G(t) Plasma glucose concentration [mmol/l] 
RGT Renal glucose threshold [mmol/l] 
Vp Glucose distribution volume [l/kg] 
mb Body mass [kg] 
Referring to Equation (2), the renal glucose clearance rate, RGC(t), models glucose 
removal by the kidney above the renal glucose threshold, RGT, using a linear 
relationship proportional to the glucose concentration above RGT and the glomerular 
filtration rate, GFR.  From the study by Johansen et al. [16], this linear approximation 
is acceptable.  Linear models have also been used in AIDA [17] by Lehmann et al. 
[18] and by Arleth et al. [19].  
 
Insulin absorption from subcutaneous injection or infusion has been widely studied 
since Binder [20].  A novel, compartmental model of subcutaneous insulin absorption 
kinetics specifically developed for diabetes decision support has been presented [21, 
22].  The model accounts for the volume and concentration dependence of regular 
human insulin absorption, and models the absorption kinetics of 6 insulin types 
including monomeric insulin (MI) and insulin glargine.  Additionally, insulin injected 
or infused subcutaneously or intravenously can also be modelled.  A schematic of the 
model adapted from [22] is shown in Figure (1).  This model is used in this study, 
which is the first application of the developed model in the control of Type 1 diabetes. 
 
(Figure (1) here) 
 
Modelling of meal glucose rate of appearance (Ra) including the digestion, absorption 
and transport of glucose is a complex process not widely studied [23].  Meal 
carbohydrate amount and type are the main factors affecting meal glucose Ra or P(t) 
in Equation 1 and 6 [24, 25].  However, clinical models of glucose Ra almost 
universally accept input of meal glucose amount only [18, 26]. Glucose equivalent 
carbohydrate (GEC) introduced by Yates et al. [23] to express carbohydrate values as 
monosaccharide equivalents necessarily depends on an a priori known content of the 
carbohydrate type within the meal to be consumed which is typically unavailable. 
Carbohydrate counting is a technique [27-29] commonly taught by diabetes care 
providers to improve glycaemic management.  Glycaemic index (GI), a measure of 
the effect of carbohydrate type, is not easily calculable for mixed meals [30] nor 
readily available like carbohydrate content.   
 
The minimal models of meal glucose Ra by Worthington [31] and Lehmann et al. [17, 
18] form the basis of the model used in this study.  Referring to Figure (2) and 
Equations (3-5), the model consists of two compartments for the stomach and gut, 
with linear gastric emptying and gut-absorption rates to describe the plasma glucose 
Ra in Equation (6).  Another simplification is the expression of meal carbohydrate 
content (in grams) as equivalent to the same mass of glucose monosaccharide 
regardless of the meal carbohydrate type [23].  Again, such meal data is typically 
unavailable in a clinical setting.  As such, the complex digestion processes such as the 
hydrolysis of polysaccharides, are assumed linear and lumped into the simplified 
processes above.   
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where: 
STO(t)  Mass of carbohydrate/glucose in the stomach [g] 
GUT(t)   Mass of carbohydrate/glucose in the gut [g] 
GABS  Gut carbohydrate/glucose absorption rate [g/min] 
GABSmax Maximum gut carbohydrate/glucose absorption rate  [g/min] 
k6  Carbohydrate/glucose gastric emptying rate [min-1] 
k7  Carbohydrate/glucose gut-absorption rate [min-1] 
uCHO(t)  Meal carbohydrate/glucose input [g/min] 
P(t)  Meal plasma glucose rate of appearance [mmol/l.min] 
Vp  Glucose plasma distribution volume [l/kg] 
mb  Body mass [kg] 
 
(Figure (2) here) 
 
Worthington [31] found the one-compartment model with time delay had the smallest 
fitting error.  However, this result was obtained with a model fit to plasma glucose 
data and is dependent on the model of glucose kinetics used.  Lehmann et al. [18] uses 
a ‘complex’ function to describe the gastric emptying rate from the stomach 
compartment.  This study uses a linear transport rate, k6 while the glucose input into 
the stomach compartment, uCHO(t) is described by a delta function.  Similar to the 
saturable gastric emptying rate of Lehmann et al. [18], this study incorporates a 
saturable gut-absorption rate, GABSmax.  Saturable gut-absorption has been postulated 
by Korach-Andre et al. [32] in experiments using relatively large starch meals.  
However, this difference is likely to be small considering the minimal nature of both 
models.  Referring to Figure (3), the effective gut absorption rate is shown as a 
function of the mass of carbohydrate/glucose in the GUT compartment.  The addition 
of the saturable term GABSmax effectively makes the gut absorption rate nonlinear as 
a function of the amount of carbohydrate in the gut.  This dynamic is similar to that of  
the nonlinear three compartment model of Dalla Man et al. [26].  The Dalla Man et al. 
model consists of dual stomach compartments with a nonlinear gastric emptying rate 
with 4 identified parameters.  Nonlinear gastric emptying term is described by a 
hyperbolic tangent function as a function of the proportion of the consumed 
carbohydrate remaining in the stomach.  There is no saturation term considered for 
large, absolute meals.  
 
(Figure (3) here) 
 
Referring to Table (1), the values of patient-independent model population constants 
are a priori identified from literature.  The renal glucose threshold, RGT has been 
shown to vary considerably in Type 1 diabetes [16] but median values of 10mmol/l 
have been widely reported.  The glucose distribution volume, Vp is taken to be 
0.22l/kg, the same value used by Lehmann et al. [18].  The glomerular filtration rate, 
GFR is taken as 0.12l/min or 120ml/min which reflects the average adult GFR of 
125ml/min [33].   
 
In a study by Dalla Man et al. [34], the maximum meal Ra (Rameal) was ~8-
9mg/kg.min after an oral dose of 1g/kg glucose.  In the study by Korach-Andre [32], 
the exogenous meal Ra (Raexo) was approximately 7-9mg/kg.min for a meal of 4g/kg 
of starch (~4.4g/kg glucose).  Despite the fourfold increase in glucose load, the 
maximum Ra remains at ~9mg/kg.min or ~0.72g/min for an average adult.  In a study 
by Noah et al. [35], a higher figure still of 11mg/kg.min is reported in a porcine 
model. The maximum value of the rate of gut absorption is taken as 1.1g/min using the 
Noah et al. study as a basis, assuming a 100kg body weight. 
 
The proportion of glucose lost to first pass splanchic uptake is still being debated with 
proportions from negligible [36, 37] to as high as 30\% reported in some studies [38]. 
As there will be no tracer data in the intended application of the model, negligible 
losses from first-pass splanchnic sequestration and complete absorption is assumed 
for simplicity  [39] with complete absorption of meal glucose.  The values of k6 and k7 
are optimised using nonlinear least squares to model-independent mixed-meal tracer 
glucose Ra data [34] (results not shown).   
 
(Table (1) here) 
 
The values of CNS, EGP0-G and pG are derived from results of studies by Del Prato et 
al. [40, 41].  Like the minimal model of Bergman et al. [42], the model is unable to 
differentiate non-insulin mediated glucose uptake from production, which are lumped 
in a linear relationship with glucose.  Referring to Figures (4-5), total body glucose 
uptake (TBGU) and hepatic glucose production (HGP) data from [40, 41] are used to 
identify CNS, EGP0-G and pG.  Data at glucose exceeding the approximate RGT of 
10mmol/l are ignored to eliminate the need to evaluate renal glucose clearance, RGC, 
and associated errors.  Under fasting and insulinopenic conditions, the P(t) and 
SIG(t)Q(t) terms of Equation (1) can be further eliminated.  By the linear definition of 
the effect of hyperglycaemia on TBGU, CNS can then be derived as the ‘virtual’ y-
intercept of the linear TBGU curve.  The term ‘virtual’ is used as no glucose uptake is 
theoretically possible at zero glucose.  The central nervous system glucose uptake 
CNS is saturated at 3.3mmol/l and is relatively insensitive to insulin and glucose [43, 
44].  At euglycaemia, CNS accounts for ~70% of all non-insulin mediated glucose 
uptake [45] and this proportion is likely to increase with hypoglycaemia.  Hence, the 
use of the term CNS for the virtual y-intercept of the linear TBGU curve is justified. 
 
Similarly, by the linear definition of the effect of hyperglycaemia on HGP, EGP0-G is 
the y-intercept of the linear HGP curve and pG the slope of the combined TBGU and 
HGP curve.  Hence, pG is similar to the minimal model glucose effectiveness, SG but 
defined under conditions of insulinopenia or sub-basal insulin, rather than basal 
insulin [46].   
 
Unlike the minimal model, the insulin model in this study models the absolute insulin 
concentration, not insulin concentration above basal.  In Type 1 diabetes, conditions 
of basal insulin are not necessarily met all the time.  Using data from [41] for an 
insulinopenic normal cohort (Figure (4)), values of CNS=1.4mg/kg.min, EGP0-
G=2.6mg/kg.min and pG=0.006min-1 are obtained compared CNS=1.3mg/kg.min, 
EGP0-G of 3.0mg/kg.min and pG=0.009min-1 under basal insulin conditions (figure not 
shown).  Compared to insulinopenia, the presence of basal insulin results in 
overestimation of pG although this value is still approximately half that of published 
values of the minimal model SG for a normal cohort ~0.024min-1 [46].   
 
(Figure (4) here) 
 
Using the data of [40] for an IDDM cohort under basal insulin (Figure (5)), values of 
CNS=1.7mg/kg.min, EGP0-G=3.0mg/kg.min and pG=0.006min-1 are obtained.  Hence, 
pG of the normal, insulinopenic cohort [41] is similar to the IDDM cohort under basal 
insulin [40].  This result is logical since SG is decreased in IDDM [46] while basal 
insulin increases SG, either by increased glucose uptake [44] or suppression of 
endogenous glucose production [41].  In IDDM, the pG obtained is also approximately 
half that of published SG values of ~0.013min-1 [46].  One explanation is the 
elimination of the data at high glucose concentrations from the pG analysis, which if 
unaccounted for would include the effect of urinary glucose excretion, thereby 
increasing the ‘effective’ glucose uptake.  From this investigation, it can be deduced 
that for an IDDM cohort under conditions of insulinopenia, pG must have an upper 
bound of 0.006min-1, which is assumed in this study.  The values of CNS obtained are 
in agreement with [45, 47, 48], and the assumption that CNS is approximately equal to 
the virtual y-intercept of the linear TBGU curve is valid.  A summary of the values of 
the model constants are shown in Table 1.   
 
(Figure (5) here) 
 
3. METHODS 
 
3.1 Patient cohort 
 
The patient data used in this study is obtained from AIDA on-line2, the web-based 
version of the AIDA educational diabetes program [49].  AIDA on-line2 incorporates 
the physiological model developed by Lehmann et al. [18] and can simulate 
glycaemic levels for any insulin or meal stimuli over a period of one day.  The patient 
data (n=40) for this study were obtained from sample diabetes case scenarios 
available with AIDA on-line2.  Referring to Table (2), each patient case is unique in 
body weight, meals/carbohydrates consumed, and insulin treatment.  Each patient also 
has unique clinical variables of hepatic and peripheral insulin sensitivity, glucose 
renal threshold, and glomerular filtration rate.  Hence, the AIDA on-line2 cohort 
represents a broad range of patients and possible clinical behaviour.  To retrieve the 
blood glucose, plasma insulin and meal glucose absorption rate from AIDA on-line2, 
the ‘Advanced’ display is selected to output the data in text format.  A sample of this 
data is shown in Figure (6). 
 
(Table (2) here) 
(Figure (6) here) 
 
3.2 Simulation method 
 
For in silico simulation, the virtual patient method is used [50, 51].  This method has 
been utilised to develop effective glycaemic control protocols by simulating the 
physiological glycaemic response to glucose and insulin stimuli [50-52].  The 
glycaemic responses are generated with patient specific SI(t) profiles derived from 
retrospective data.  This clinically validated method [50] enables extensive 
simulations to be performed in a short time for rapid development and testing of any 
control methodology.  The in silico simulation was performed using MATLAB® (The 
Mathworks, Natick, MA, USA) implemented on a PC notebook (Pentium M 1.7Ghz). 
 
To obtain the retrospective SI(t) patient data profiles, the model is first fitted to the 
data using the linear and convex, integral-based parameter identification method [53].  
Equation (1) can be expressed in a generic integral form (Equation (7)) for period ti-1 
to ti, which is a set of linear equations (Equation (8-9)). All quantities in Equation (7) 
are modelled and as such, are known except for G(t).   
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AIDA on-line2 uses a first-order Euler integration method with a 15min step-size to  
solve the plasma glucose model equation [54].  To determine G(t) to solve Equation 
(7), the AIDA on-line2 glucose data is linearly interpolated to obtain a piecewise 
linear G(t) function (Equation (8)). 
 
The ti–ti-1 time interval for the optimisation of SI(t) is chosen arbitrarily as 10mins.  
Equation (8) is solved using a proprietary MATLAB® linear solver.  Referring to 
Figure (7) and Equations (9-10), a stepwise, time-variant SI(t) with a 10min step 
interval is obtained. 
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(Figure (7) here) 
 
A proprietary MATLAB® numerical ode solver is used to solve the model equations 
with a 1min time step.  Biphasic insulin preparations are treated as in AIDA with the 
insulin response assumed to be a superposition of the individual components of the 
preparation [18].  This is an acknowledged simplification considering the large variety 
and lack of data on such preparations.  
 
The numerical solution to the model equations form the in silico simulation tool.  
With the set of 40 virtual patient SI(t) profiles, any meal or sc insulin input and its 
effect on glycaemia can be simulated with the assumption that SI is independent of the 
inputs administered i.e. the virtual patient.  This opens the possibility of simulating 
any glycaemic control protocol, even current clinical methods [55-57].  An initial 
validation would be to replicate long-term glycaemic control outcomes e.g. HbA1c. 
 
 
4. RESULTS 
 
To gauge the model fit to data, the absolute and absolute percentage errors of the G(t) 
model fit to the AIDA on-line2 patient data cohort is shown in Table (3) and (4).  In 
Table (3), per patient errors are shown while the total errors over the entire cohort is 
shown in Table (4).  A sample G(t) fit is also shown in Figure (8). 
 
(Figure (8) here) 
(Table (3-4) here) 
 
From Table (3), the per patient median (95% range) absolute percentage error in G(t) 
is 1.24% (0.09-4.85%) which translates into a per patient absolute error in G(t) of  
0.11mmol/l (0.01-0.43mmol/l).  Over the entire cohort the figures are 1.33% (0.08-
7.20%) and 0.12mmol/l (0.01-0.56mmol/l) which are similar.  The errors reported are 
extremely low and within the measurement errors of clinical methods of glucose 
measurement in current use.  This shows that the model and SI identification method 
is capable of capturing all patient G(t) dynamics, which will produce a more 
physiologically accurate simulation. 
 
5. CONCLUSIONS 
 
An in silico simulation tool is presented that utilises an extended model of glucose 
kinetics, a simple glucose rate of appearance model, and the novel application of a 
subcutaneous insulin pharmacokinetic model.  Models are identified to a 
physiological cohort of Type 1 diabetes virtual patients.  To corroborate the approach 
initially, an in silico simulation with the data from the patient cohort using the virtual 
patient simulation method is planned.   
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Figure 1: Structure of the sc insulin absorption kinetic model.  Model is characterised by a 
common hexameric state compartment for RI, NPH and lente insulins (xh) while those for insulin 
glargine and ultralente (xh,ulen and xh,gla) are separate.  A crystalline state compartment for NPH 
(cNPH), lente (clen) and ultralente (culen) insulins, and a precipitate compartment for insulin 
glargine (pgla) model these protraction mechanisms.  All insulin flows through a common a 
dimeric-monomeric state compartment (xdm), interstitium compartment (xi), and finally into the 
plasma (I).  Adapted from [22] 
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Figure 2: Structure of the meal glucose rate of appearance model.  The model is characterised by 
a delta function to describe meal glucose input (uCHO(t)), linear gastric emptying (k6) and gut 
absorption (k7) rates, and saturable gut absorption (GABSmax) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Qualitative plot of the effective gut absorption rate as a function of the mass of 
carbohydrate/glucose in the GUT compartment.  While the processes of gastric emptying is 
linear, the addition of the saturable gut absorption term, GABSmax of 1.1g/min effectively makes 
the process of gut absorption, and hence meal glucose Ra nonlinear.  At low glucose levels in the 
gut, the effective gut absorption rate is 0.00971/min.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Using HGP and TBGU data from [41] for an insulinopenic normal cohort, values of 
CNS=1.4mg/kg.min, EGP0-G=2.6mg/kg.min and pG=0.006min-1 can be calculated by linear 
regression 
 
 
 
 
 
Figure 5: Using HGP and TBGU data of [40] for an IDDM cohort under basal insulin, values of 
CNS=1.7mg/kg.min, EGP0-G=3.0mg/kg.min and pG=0.006min-1 can be calculated by linear 
regression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 6: Sample raw blood glucose, plasma insulin level and glucose absorption rate data from 
AIDA2 on-line [49] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Sample patient SI(t) profile as obtained from model fit.  Note the 10min interval for 
fitting the stepwise, time-variant SI(t)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: G(t) model fit to glucose measurement data for Patient 1 shown with the glucose 
measurement data from AIDA on-line2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLES 
 
Table 1: A priori identified model constants obtained from literature except the linear gastric 
emptying and gut absorption rates (k6 and k7 respectively) which are optimised using nonlinear 
least squares to model-independent, mixed-meal tracer glucose Ra data [34] 
 
Model constants Values [units] 
GABSmax 1.1 [g/min] 
pG 0.0060 [min-1] 
CNS 1.7 [mg/kg.min] 
EGP0-G 3.0 [mg/kg.min] 
GFR 0.12 [l/min] 
RGT 10 [mmol/l] 
VP 0.22 [l/kg] 
k6 0.0388 [min-1] 
k7 0.0097 [min-1] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Details of the patient cohort (n=40) from AIDA2 on-line showing body weight, total carbohydrate consumed, total prandial insulin dose, total basal insulin 
dose, and the unique clinical variables of hepatic and peripheral insulin sensitivity, glucose renal threshold, and glomerular filtration rate 
 
Case 
number 
Body 
weight 
[kg] 
Total 
carbohydrate 
consumed 
[g] 
Total 
prandial 
insulin dose 
[U] 
Total basal 
insulin dose 
[U] 
Renal 
threshold 
Renal 
function 
Hepatic 
insulin 
sensitivity 
Peripheral 
insulin 
sensitivity 
1 70 130 7 30 Normal Normal Reduced Reduced 
2 68 180 13 10 High Normal Increased Increased 
3 70 120 9 13 Normal Normal Normal Increased 
4 60 180 13 12 Normal Normal Increased Increased 
5 98 180 12 12 Normal Normal Normal Normal 
6 76 120 8 28 Normal Normal Reduced Increased 
7 70 90 7 24 Normal Normal Increased Reduced 
8 70 120 10 20 Normal Normal Reduced Increased 
9 70 180 12 12 High Normal Normal Increased 
10 70 120 15 8 Normal Normal Normal Increased 
11 70 205 16 22 Normal Normal Normal Increased 
12 70 185 24 20 Normal Normal Reduced Increased 
13 76 100 8 26 Normal Normal Normal Increased 
14 65 70 5 20 Normal Normal Reduced Normal 
15 99 115 6 42 Normal Normal Reduced Normal 
16 70 180 9 32 Normal Normal Reduced Increased 
17 70 110 10 24 Normal Normal Reduced Increased 
18 60 165 18 36 High Normal Reduced Increased 
19 60 180 12 12 Normal Normal Normal Increased 
20 70 105 8 36 Normal Normal Normal Increased 
21 98 295 34 40 Normal Normal Reduced Reduced 
22 75 70 Biphasic 40 Normal Normal Reduced Reduced 
23 87 177 38 12 Normal Normal Reduced Increased 
24 76 95 7 24 Normal Normal Normal Increased 
25 70 120 18 28 Normal Normal Reduced Normal 
26 80 170 Biphasic 20 Normal Normal Normal Increased 
27 70 120 9 13 Low Normal Normal Normal 
28 75 85 5 40 Normal Normal Normal Increased 
29 83 60 12 25 Normal Normal Reduced Normal 
30 80 165 16 36 Normal Normal Reduced Increased 
31 99 220 29 14 Low Normal Normal Increased 
32 90 70 0 28 Normal Normal Reduced Reduced 
33 98 180 0 18 Normal Normal Normal Increased 
34 60 175 17 13 High Normal Normal Increased 
35 60 170 22 10 Normal Normal Normal Increased 
36 70 100 8 32 Normal Normal Reduced Increased 
37 70 105 9 36 High Normal Reduced Reduced 
38 70 95 Biphasic 26 Normal Normal Normal Reduced 
39 70 110 12 35 High Normal Reduced Increased 
40 76 100 7 30 Normal Normal Normal Normal 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Per patient absolute and absolute percentage G(t) model fit error to the patient cohort data (n=40) from AIDA2 on-line 
 
 
Absolute % G(t) fit error [%] 
 
 
Absolute G(t) fit error [mmol/l] 
 Case number 
Median 5
th  
percentile 
95th 
percentile Median 
5th  
percentile 
95th 
percentile 
1 0.84 0.08 2.87 0.10 0.01 0.43 
2 1.28 0.05 7.14 0.10 0.00 0.50 
3 1.19 0.02 3.56 0.12 0.00 0.37 
4 1.72 0.05 7.84 0.12 0.00 0.42 
5 0.94 0.11 3.24 0.11 0.01 0.36 
6 1.25 0.04 4.89 0.13 0.00 0.53 
7 1.93 0.11 4.52 0.07 0.00 0.20 
8 0.96 0.05 4.46 0.09 0.00 0.49 
9 1.03 0.10 2.94 0.12 0.01 0.39 
10 1.92 0.28 4.27 0.17 0.02 0.39 
11 3.09 0.20 14.04 0.20 0.01 2.39 
12 1.23 0.05 8.78 0.13 0.00 0.70 
13 1.08 0.09 4.80 0.07 0.00 0.26 
14 0.47 0.04 3.43 0.05 0.00 0.47 
15 1.00 0.12 3.84 0.08 0.01 0.29 
16 1.61 0.11 5.84 0.18 0.01 0.59 
17 1.31 0.06 4.38 0.13 0.00 0.38 
18 3.34 0.32 7.84 0.21 0.03 0.80 
19 1.23 0.09 4.14 0.16 0.01 0.52 
20 2.89 0.17 21.39 0.13 0.00 0.89 
21 2.73 0.49 7.17 0.32 0.06 0.93 
22 0.88 0.11 3.95 0.09 0.01 0.50 
23 1.50 0.03 4.96 0.11 0.00 0.33 
24 1.98 0.21 6.67 0.14 0.01 0.43 
25 1.37 0.02 7.44 0.09 0.00 0.59 
26 0.67 0.09 2.48 0.07 0.01 0.31 
27 0.69 0.08 2.74 0.06 0.01 0.27 
28 0.81 0.09 6.27 0.05 0.00 0.36 
29 0.81 0.15 4.48 0.07 0.01 0.40 
30 9.36 0.98 37.10 0.72 0.06 2.56 
31 1.16 0.11 8.67 0.08 0.01 0.44 
32 0.60 0.06 2.36 0.06 0.01 0.28 
33 0.93 0.13 2.72 0.10 0.01 0.29 
34 1.84 0.01 5.93 0.15 0.00 0.44 
35 3.30 0.18 11.70 0.26 0.01 1.06 
36 1.36 0.19 5.05 0.12 0.01 0.39 
37 0.94 0.03 3.38 0.12 0.00 0.46 
38 0.73 0.08 3.07 0.08 0.01 0.40 
39 1.29 0.04 5.53 0.11 0.00 0.51 
40 1.70 0.20 7.20 0.10 0.01 0.31 
Median 1.24 0.09 4.85 0.11 0.01 0.43 
Range 0.47-9.36 0.01-0.98 2.36-37.10 0.05-0.72 0.00-0.06 0.20-2.56 
 
 
 
 
 
 
 
 
 
 
Table 4: Total absolute and absolute percentage G(t) model fit error to the patient cohort data (n=40) from AIDA2 on-line 
 
 
Absolute % G(t) fit error [%] 
 
 
Absolute G(t) fit error [mmol/l] 
 
Median 5
th  
percentile 
95th 
percentile Median 
5th  
percentile 
95th 
percentile 
1.33 0.08 7.20 0.12 0.01 0.56 
 
 
 
 
